DUXAP9 and metastatic malignant neoplasm in the lymph nodes: Overexpression of DUXAP9 was frequently observed in moderate/poor pathological grade, advanced clinical stage, lymph node metastasis, worse overall survival (OS), and worse disease‐specific survival (DSS).